To The Moon

🌟🌟🌟In a market gripped by volatility, few names offer the rare blend of stability, scale and upside potential like $PING AN(02318)$  $Ping An Ins HK SDR2to1(HPAD.SI)$ .  As China's largest integrated financial group, Ping An isn't just an insurance play.  It is a full spectrum financial powerhouse with deep roots in life and health insurance as well as banking and asset management.  After a solid Q1 25 and bullish analyst sentiments, Ping An is flashing strong buy signals for investors seeking both resilience and rerating potential.

Ping An Q1 2025

Ping An's Q1 25 results were excellent in terms of operational discipline and strategic execution despite a turbulent macro environment. 

Operating profit attributable to shareholders rose 2.4% year over year to RMB 7.91 billion despite subdued domestic demand and market volatility. 

Life and Health new business value (NBV) surged 34.9% year over year to RMB 12.89 billion, with NBV margin expanding 10.4% to 32%, a clear sign of high quality growth. 

Insurance revenue edged up 0.7% year over year to RMB 81.15 billion, while the combined ratio improved by 3.0 points to 96.6%, reflecting better underwriting discipline. 

Retail customer base grew to almost 245 million with a 98% retention rate among customers holding 4 or more contracts. 

Total assets climbed above RMB 13.18 trillion, reinforcing Ping An's fortress like balance sheet. 

Insurance funds investment yield rose to 1.3%, up 0.2 points year over year despite market headwind. 

Ping An also deepened its health and senior care ecosystem, now covering 75 cities and partnering with all top 100 hospitals and over 239,000 pharmacies across China.  Nearly 63% of retail customers are now entitled to health related service benefits, a strategic moat few insurers can match. 

Why HPAD (Ping An Singapore SDR) Stands out

HPAD offers a 2:1 ratio to Ping An's HK listed shares, giving Singapore investors efficient exposure to a Hang Seng heavyweight stock. 

As HPAD is traded on the SGX in Singapore Dollars, it eliminates foreign exchange risks for investors. 

Lower minimum investment cost, making HPAD ideal for portfolio diversification. 

HPAD is part of the elite HK SDRs suite which offers thematic exposure to China's financial and healthcare transformation. 

Ping An's integrated finance model creates a virtuous flywheel, cross selling across insurance, banking and health platforms to deepen customer engagement and boost margins.  Ping An's tech driven approach, including AI powered underwriting and digital health services, positions it as a leader in Asia. 

Analysts Are Bullish and For Good Reason 

According to consensus estimates, Ping An's 12 month price target averages HKD 62.64, with upside potential of 12% from current price levels.  Nomura and other major financial managers maintain Buy rating, citing strong fundamentals and improving margins across core segments. 

Macro Tailwinds - Defensive stock to buy and hold 

Ping An is well positioned amid 2H25 macro crosswinds :

China's policy pivot towards domestic consumption and healthcare aligns perfectly with Ping An's integrated strategy. 

Rising geopolitical tensions and tariff uncertainty have investors rotating into defensive, dividend paying stocks. 

Valuation remains compelling with a P/E ratio of only 2.24 and a dividend yield of 5.58%.

Concluding Thoughts - Ping An is a great buy 

Ping An Insurance isn't just a defensive anchor. It is a growth engine disguised as an insurer.  With robust Q1 25 results, a fortress like balance sheet and a strategic pivot into health and senior care, Ping An is quietly building the future of integrated finance in China. 

For investors seeking great dividends, growth and resilience, $PING AN(02318)$  $Ping An Ins HK SDR2to1(HPAD.SI)$ is a rare triple treat and a compelling Buy heading into 2H25. Ping An isn't just an opportunity.  It is a strategic move for 2H25 and beyond. 

@Daily_Discussion  @TigerStars  @Tiger_SG  @Tiger_comments  @CaptainTiger  @TigerClub